Food and Drug Administration Perspective on Negative Symptoms in Schizophrenia as a Target for a Drug Treatment Claim
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Negative symptoms of schizophrenia are not adequately addressed by available treatments for schizophrenia. Thus, it is reasonable to consider them as a target for a drug claim. This article describes the thought process that the Food and Drug Administration (FDA) will undertake in considering negative symptoms of schizophrenia as a novel and distinct drug target. Beyond this basic question, this article identifies a number of design issues that the FDA needs to consider regarding how best to conduct studies to support claims for this target. These design issues include (1) what population to study, (2) what phase of illness to target, (3) whether to focus on the negative symptom domain overall or on some specific aspect of negative symptoms, (4) the role of functional measures in negative symptom trials, and (5) optimal designs for targeting drugs for add-on therapy or broad-spectrum agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Cited by
The NIMH-MATRICS Consensus Statement on Negative Symptoms
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., & Marder, S. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj053 · Cited by 1,311
The brief negative symptom scale: Psychometric properties
Kirkpatrick, B., Strauss, G. P., Nguyen, L., Fischer, B. A., Daniel, D. G., Cienfuegos, A., & Marder, S. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq059 · Cited by 895
The clinical assessment interview for negative symptoms (CAINS): Final development and validation
Kring, A. M., Gur, R. E., Blanchard, J. J., Horan, W. P., & Reise, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010109 · Cited by 726
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias, G., & Remington, G. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn094 · Cited by 594
Emotional Response Deficits in Schizophrenia: Insights From Affective Science
Kring, A. M., & Moran, E. K. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn071 · Cited by 458
Metadata
- Authors
- Laughren, T., & Levin, R.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-03
- Volume
- 32
- Issue
- 2
- Pages
- 220-222
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2160712198
- Cited by
- 79
- References
- 1
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Food and Drug Administration Perspective on Negative Symptoms in Schizophrenia as a Target for a Drug Treatment Claim. https://app.cochat.ai/papers/10.1093/schbul/sbi039
- The paper
- Laughren, T., & Levin, R. (2006). Food and Drug Administration Perspective on Negative Symptoms in Schizophrenia as a Target for a Drug Treatment Claim. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbi039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.